EMEA-001624-PIP01-14-M05 - paediatric investigation plan

Nemolizumab

Key facts

• Active Substance:
  Nemolizumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0201/2022
• PIP number:
  EMEA-001624-PIP01-14-M05
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of atopic dermatitis
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Galderma International S.A.S.

  E-mail: [e-mail]

  Tel. [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  21/06/2022

Decision

P/0201/2022 : EMA decision of 21 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M05)

AdoptedReference Number: EMA/266713/2022